---
title: "RNXT: Strong commercial growth and clinical data position RenovoCath for major oncology market impact"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/298948734.md"
description: "A high-margin oncology platform is scaling commercial adoption of its FDA-cleared RenovoCath device, targeting a $400M+ U.S. market and expanding into new indications. Interim Phase III data show a 6-month survival benefit and fewer adverse events in pancreatic cancer, supporting strong revenue growth and future label expansion.Original document: RenovoRx, Inc. [RNXT] Slides Release — Sep. 14 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-09-14T17:12:42.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/298948734.md)
  - [en](https://longbridge.com/en/news/298948734.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/298948734.md)
generator: "portal-rs"
---

# RNXT: Strong commercial growth and clinical data position RenovoCath for major oncology market impact

A high-margin oncology platform is scaling commercial adoption of its FDA-cleared RenovoCath device, targeting a $400M+ U.S. market and expanding into new indications. Interim Phase III data show a 6-month survival benefit and fewer adverse events in pancreatic cancer, supporting strong revenue growth and future label expansion.

Original document: RenovoRx, Inc. \[RNXT\] Slides Release — Sep. 14 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [RNXT.US](https://longbridge.com/en/quote/RNXT.US.md)

## Related News & Research

- [RNXT: Record revenue, raised guidance, and expansion beyond core market signal strong growth](https://longbridge.com/en/news/295714627.md)
- [EXCLUSIVE: Renovorx Advances Its Targeted Pancreatic Cancer Therapy, Pivotal Data Expected in 2027](https://longbridge.com/en/news/295533800.md)
- [What the West misses when it judges Chinaâs dogged AI pursuit](https://longbridge.com/en/news/300214004.md)
- [BrightSpring Health Targets Growth Through Specialty Pharmacy, M&A and AI](https://longbridge.com/en/news/300219437.md)
- [MaxLinear (MXL) Draws Fresh Attention, Does It Look Fully Valued?](https://longbridge.com/en/news/300242448.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**